Eric Adler Sells 3,382 Shares of Lexeo Therapeutics (NASDAQ:LXEO) Stock

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) insider Eric Adler sold 3,382 shares of the business’s stock in a transaction that occurred on Friday, October 17th. The stock was sold at an average price of $8.94, for a total transaction of $30,235.08. Following the completion of the sale, the insider directly owned 73,261 shares of the company’s stock, valued at $654,953.34. This represents a 4.41% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Eric Adler also recently made the following trade(s):

• On Monday, August 18th, Eric Adler sold 608 shares of Lexeo Therapeutics stock. The stock was sold at an average price of $4.67, for a total transaction of $2,839.36.

Lexeo Therapeutics Stock Up 9.2%

LXEO stock opened at $9.58 on Friday. The company has a market capitalization of $517.32 million, a price-to-earnings ratio of -2.94 and a beta of 1.66. Lexeo Therapeutics, Inc. has a 12 month low of $1.45 and a 12 month high of $11.72. The firm has a 50 day moving average of $5.91 and a two-hundred day moving average of $4.40.

Lexeo Therapeutics (NASDAQ:LXEO) last posted its earnings results on Thursday, August 14th. The company reported ($0.60) EPS for the quarter, topping the consensus estimate of ($0.64) by $0.04. On average, research analysts expect that Lexeo Therapeutics, Inc. will post -3.14 EPS for the current fiscal year.

Institutional Trading of Lexeo Therapeutics

Hedge funds have recently bought and sold shares of the stock. CWM LLC boosted its holdings in Lexeo Therapeutics by 150.3% in the 2nd quarter. CWM LLC now owns 10,351 shares of the company’s stock valued at $42,000 after purchasing an additional 6,216 shares during the period. Ethic Inc. bought a new stake in Lexeo Therapeutics in the 2nd quarter valued at $44,000. Cerity Partners LLC bought a new stake in Lexeo Therapeutics in the 2nd quarter valued at $50,000. Intech Investment Management LLC boosted its holdings in Lexeo Therapeutics by 20.7% in the 2nd quarter. Intech Investment Management LLC now owns 13,682 shares of the company’s stock valued at $55,000 after purchasing an additional 2,342 shares during the period. Finally, Vanguard Personalized Indexing Management LLC bought a new stake in Lexeo Therapeutics in the 2nd quarter valued at $60,000. 60.67% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several analysts have commented on the stock. HC Wainwright boosted their target price on shares of Lexeo Therapeutics from $9.00 to $15.00 and gave the stock a “buy” rating in a research report on Tuesday, October 7th. Oppenheimer began coverage on shares of Lexeo Therapeutics in a report on Thursday, July 31st. They set an “outperform” rating and a $20.00 price objective for the company. Leerink Partners upped their price objective on shares of Lexeo Therapeutics from $9.00 to $20.00 and gave the stock an “outperform” rating in a report on Tuesday, October 7th. Guggenheim began coverage on shares of Lexeo Therapeutics in a report on Wednesday. They set a “buy” rating and a $30.00 price objective for the company. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lexeo Therapeutics in a report on Wednesday, October 8th. Seven research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Lexeo Therapeutics has an average rating of “Moderate Buy” and an average price target of $18.86.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.